GLP-1 pipeline drugs — the next generation of incretin-based therapies including triple GLP-1/GIP/glucagon receptor agonists, amylin/GLP-1 combinations, and novel delivery systems — represent the advancing pharmaceutical pipeline that will progressively raise the standard of metabolic disease treatment above current best-in-class options, with the GLP-1 Drug Market reflecting the...

GLP-1 Market to Reach USD 133.92 Billion by 2034, Growing at 10.9% CAGR: Polaris Market Research According to Polaris Market Research, the global GLP-1 market was valued at USD 52.82 billion in 2025 and is projected to reach USD 133.92 billion by 2034. The market is estimated at USD 58.48 billion in 2026 and is expected to grow at a CAGR of 10.9% during 2026–2034. Expansion is being...